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S234 Poster Session IRelapsing disease is still the major cause of treatment failure. Addi-
tional strategies, such as maintenance therapy with novel agents or
judicious use of donor lymphocyte infusions merit further investiga-
tion for converting PR to CR and reducing relapse risk.204
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Following myeloablative conditioning due to high treatment-re-
lated mortality (TRM), some studies have shown an inferior out-
come using allogeneic HSCT compared to autologous transplant.
More recently, non-myeloablative (NMA) and reduced intensity
conditioning (RIC) for allogeneic HSCT was introduced. A prereq-
uisite for this approach is a significant graft-versus-myeloma effect,
which has not clearly been demonstrated. Between 1997 and 2005,
177 patients were reported to the CIBMTR following NMA
(n5 120) or RIC (n5 57) and an allogeneic HSCT from an HLA-
identical sibling donor. Median age was 50 years (range 24-69).
Planned tandem autologous transplant followed by allogeneic
HSCT was given to 105 of these patients. Most patients were given
peripheral blood stem cells (98%). Outcomes, with a median follow-
up of 55 months (range 3-98) and 25 months (range 3-76) respec-
tively for allogeneic HSCT and autologous transplant followed by
allogeneic HSCT, see Table below.
The following variables were significant in univariate outcomes
analyses and were therefore used in the multivariate modelling:
age, sex, performance status, IgG vs. non IgG myeloma, disease sta-
tus and chemosensitivity, prior lines of chemotherapy, donor-recip-
ient sex match, NMA vs. RIC, year of transplant and GVHD as the
time dependent covariate. The only factor on multivariate analysis
that increased the risk of TRM was acute GVHD (RR 2.38,
p5 0.018). Only chronic GVHD decreased the probability of re-
lapse on multivariate (RR 0.43, p5 0.012), but this effect was not
seen in patients with IgGmyeloma (n5 97, RR 0.7, p5 0.3) in com-
parison to all other types of myeloma (n5 80, RR 0.11, p5 0.004).
Improved PFS was associated with autologous + allogeneic HSCT
(RR 3.6, p5 0.001) and absence of acute GVHD (p5 0.001), but
not chronicGVHD (RR 0.9, p5 0.7). In conclusion, patients receiv-
ing allogeneic HCT for myeloma, chronic GVHD decreased the
probability of relapse, but only in patients with non-IgG myeloma.
PFS was improved in patients receiving autologous + allogeneic
HCT and was decreased in those with acute GVHD.
Outcomes Allo only Auto1AlloNumber of patients 72 105
Acute GVHD at 100 days, grades (1-4) 47 (37-60)% 37 (28-46)%
Chronic GVHD at 3 years 55 (43-67)% 58 (43-72)%
Treatment Related Mortality (TRM) at
3 years27 (17-38)% 16 (10-25)%Relapse at 3 years 48 (36-60)% 41 (29-54)%
Progression-free survival (PFS) at 3
years25 (15-37)% 42 (20-43)%Overall Survival at 3 years 45 (33-58)% 64 (53-75)%205
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The lack of specific molecules to define the multiple myeloma
(MM) malignant cells responsible for disease development and re-
lapse has hampered the evaluation of minimal residual disease
(MRD) in MM. PC development compromises an array of sub-
populations with distinctive phenotypes. Syndecan (CD138) is ex-
pressed in plasma cells (PC) and studies using CD138+ selected
cells may be problematic since earlier progenitors may be ex-
cluded. To define myeloma bone marrow (BM) progenitor phe-
notype we developed a multicolor flow cytometry assay to
study them. We have identified a CD138- subset that co-express
CD19+, CD27+ and identical kappa or lambda light chain re-
striction as the abnormal plasma cells, as previously shown by
others. Further characterization has shown that this subset co-ex-
presses the c-Kit (CD117) (20%) and Notch-1 receptors (90%) as
the hematopoietic stem cells (HSC) CD34+ counterpart. A small
percentage of this BM cells show aldehyde dehydrogenase
(ALDH) activity. Flow sorting of CD138- was feasible with
99% purity. Isolated populations were grown in methylcellulose
with 5% PHA-leukocyte conditioned medium. CD138+ cells
did not exhibit colony formation, and neither did the CD138-/
CD38+/CD19-/CD34- cells. Instead, CD138-/CD38+/CD19+/
CD34- cells were able to grow cell colonies (.100 cells) al-
though their efficiency was low (1 in 15,000). CD34+ cells
(HSC) also were able to grow cell colonies but with a significant
lesser efficiency compared to SCF, IL-3 and GM-CSF cytokine
stimulation. Cells harvested at day 14 from CD34+ and
CD138-/CD38+/CD19+/CD34- generated colonies showed
a lympho-plasmacytoid appearance. We showed that only
CD138-/CD38+/CD19+/CD34- cells, but not CD34 +HSC, dif-
ferentiated into a more mature syndecan (CD138+) expressing
cell as determined by flow cytometry. Isolated CD138-/CD38+/
CD19+/CD34- cells shown to be relatively bortezomib-resistant
when compared to CD138+ plasma cells. The lacking expression
of mature PC markers in this MM sub-population makes us hy-
pothesize that they represent a progenitor B cells that differenti-
ate into the malignant PC. Surrogate assays for stem cell activity
(long term culture-initiating cell (LTC-IC), cobblestone-area
forming cells (CAFC) and xenotransplant models should deter-
mine cancer stem cell activity of these cells. Research studies of
these CD138- MM putative progenitor cells may lead to develop
novel treatments to target MM subpopulations that may consti-
tute the MRD reservoir.206
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Introduction: Although the number of ASCTs performed for
MM continues to increase, the optimal mobilization strategy re-
mains unclear. Additionally, concern has arisen about the impact
of age and prior lenalidomide exposure on mobilization efficacy.
High dose etoposide has been previously shown to have antitumor
activity and efficacy in progenitor cell mobilization, and has a fa-
vorable safety profile when cytokine is also given (Gianni et al.,
JCO 1992). Here, we report on the efficacy and safety of mid-
dose etoposide and G-CSF as a mobilization regimen for pts
with MM.
Methods: Between May 2004 and June 2009, 152 pts with MM un-
derwent ASCT following the use of VP-16 (375 mg/m2 on D#1 and
D#2) and G-CSF (5mcg/kg twice daily from D#3 through the final
day of collection) for mobilization. 65 pts were female, 87 were
male, and median age was 56 yrs (range 17-72). Collection was
Poster Session I S235initiated when the peripheral blood CD34 cell count was.7/ul. The
target total CD34 cell collection was 5  106 cells, and ‘‘poor mobi-
lizers’’ were defined as pts unable to collect this target in 1-2 days of
collection.
Results: Prior to mobilization, 80 (53%) pts had previously re-
ceived thalidomide, and 29 (19%) additional pts had previously
been exposed to lenalidomide, with a median treatment duration
of 6 months. All 152 pts (100%) successfully collected with one
mobilization, 143 pts (94%) successfully collected in a single
day, and the median total number of CD34 cells collected was
12  106. 61% of pts collected on D + 11 and the rest between
D + 7 and D + 13. Only 2 pts (1%) were subsequently categorized
as poor mobilizers, requiring 3 and 4 days to collect. 27 out of 29
pts who had received lenalidomide previously were found to be
good mobilizers. The median time to neutrophil engraftment
was 11 days, and the median time to a sustained platelet
count. 20,000 without transfusions for 7 days was 16 days. 31
(20%) pts required at least one supportive transfusion during
the mobilization process, and a total of 26 (17%) pts required
treatment for fevers. No pts developed MDS or AML. Neither
age, prior imid exposure, nor any other variables were associated
with poor mobilization or engraftment.
Conclusion:VP-16 and G-CSF is an effective and safe mobilization
regimen for pts with MM undergoing ASCT, producing excellent
stem cell yield with a minimum of pheresis procedures. With this
regimen, neither age nor prior imid exposure appear to adversely im-
pact stem cell collection.207
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Introduction: T-cell non-Hodgkins lymphomas (T-NHL) com-
prise a heterogeneous array of clinical and pathologic entities.
Among aggressive NHL, T cell phenotype is a poor risk factor. Cur-
rently, there is no universal standard of care regarding therapy. Re-
lying on evidence supporting a graft-versus-lymphoma (GVL) effect
in these diseases, investigators have used allogeneic transplant (al-
loHSCT) to treat T-NHL. Data regarding outcomes following al-
loHSCT for these patients remains limited.
Methods: We performed a retrospective analysis of 30 consecu-
tive patients (mean age 52, range 5-68) who received alloHSCT
for T-NHL at MSKCC, between Jan 1992 and Aug 2008. His-
tologies included anaplastic large cell (4 ALK -, 4 ALK+), an-
gioimmunoblastic (3), hepatosplenic gamma-delta (5), HTLV-1
associated (1), mycosis fungoides (2), NK/T (2), subcutaneous
panniculitis-like T-cell lymphoma (3), peripheral T cell lym-
phoma, NOS (6). Preparative regimens were ablative (9) or non-
ablative (21), grafts were unmodified (15) or ex-vivo T cell
depleted (TCD) (15). IPI, PIT and disease status were assessed
directly pre alloHSCT. Survival was estimated by the Kaplan-
Meier method, and the cumulative incidence function estimated
the probability of time to disease relapse (DR). Log-rank test
and Gray’s test were used respectively to determine whether sur-
vival and cumulative incidence functions differed by covariates of
interests.Results: Median follow up for survivors was 38 months. Two-year
overall survival (OS) was 60% (95% CI: 40-80). Log-rank test did
not reveal an association between OS and prior autoSCT, IPI,
PIT, TCD, disease status or degree of myeloablation. Pre-salvage
MIB-1/Ki-67\25% was associated with improved OS
(p5 0.007). The cumulative incidence of DR at 6 months was
30%. There were no associations between cumulative incidence of
DR and IPI, TCD, disease status, degree of myeloablation and
MIB-1/Ki-67 score.
Discussion: Two-year OS and DR at 1 year are favorable in this
population of T-NHL patients with 47% in durable remission.
Pre-salvage MIB-1/Ki-67\25% appears to be predictive of OS.
However, the ability to test for associations with clinical factors
and outcomes is limited by our small sample size and low number
of events. This study provides further support for prospective al-
loHSCT T-NHL trials including use and evaluation of prognostic
biomarkers like MIB-1/Ki-67.208
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Introduction: There remains little consensus about the best means
for mobilizing stem cells prior to ASCT. Cytokine alone, usually G-
CSF, provides easy scheduling while the combination approaches
generally provide higher cell yields and additional cytoreduction. Be-
cause of its value as a cytoreductive agent, and its lack of stem cell
damaging properties or other toxicities, we investigated the use of
mid-dose VP-16 plus G-CSF as a mobilizing regimen.
Methods: Between May 2004 and June 2009, 288 pts with the fol-
lowing diseases were mobilized with VP-16 (375 mg/m2 on D#1
and D#2) and G-CSF (5mcg/kg twice daily from D#3 through the
final day of collection): MM (152), Non-Hodgkin Lymphoma (98),
and Hodgkin Disease (38). In 14 pts, one dose of Rituximab
(375 mg/m2) was also given on D#1. 122 pts were female, 166
were male, and median age was 54 yrs (range 19-72). Stem cell col-
lection was initiated when the peripheral blood CD34 cell count
was more than 7/ul. The target total CD34 cell collection was 5 
106.
Results: Among all pts, 279 (97%) had stem cells successfully
collected after one mobilization. 9 pts (all with lymphoma) re-
quired more than one mobilization or bone marrow harvest for
yields less than 2  106. 14% of all pts required IV antibiotics
or hospitalization for fevers, and 32% of all pts needed at least
one RBC or platelet transfusion. One pt developed secondary
MDS. The median number of days collecting stem cells was 1
for MM pts and 2 for lymphoma pts, and the median total num-
ber of CD34 cells collected was 12  106 for MM pts and 6 
106 for lymphoma pts. 94% of MM pts and 43% of lymphoma
pts collected in a single day. The median time to neutrophil en-
graftment was 11 days for all pts, and the median time to a sus-
tained platelet count. 20,000 without transfusions for seven days
or longer was 16 days for MM pts and 15 days for lymphoma
pts. ‘‘Poor mobilizers’’ were defined as pts who failed to collect
5  106 cells in one or two days, and included 19% of all pts.
1% of MM pts and 40% of lymphoma pts were ‘‘poor mobi-
lizers’’(p\0.001). The pre-mobilization white blood count
(p5 0.01), platelet count (p5 0.006) and a CD34 count less
than 26/ul (p\0.001) were associated with poor mobilization
in lymphoma pts.
Conclusion:VP-16 and G-CSF is an effective and safe mobiliza-
tion regimen for pts undergoing ASCT with a low incidence of
fevers or need for supportive transfusions. A CD34 count\26/ul
in lymphoma pts appeared to predict for poor mobilization.
